GLP-1 Receptor Agonists represent a promising therapeutic approach for neurodegenerative diseases. These compounds activate the glucagon-like peptide-1 receptor, which is widely expressed in the brain and exerts neuroprotective effects through multiple signaling pathways.
This page provides comprehensive information about GLP-1 receptor agonists in neurodegeneration, including their mechanisms of action, preclinical and clinical evidence, and therapeutic implications.
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that plays crucial roles in glucose metabolism and has emerged as a attractive target for neurodegenerative disease therapy.
GLP-1 receptor agonists, originally developed for type 2 diabetes, have shown neuroprotective properties in numerous preclinical studies and are now being investigated in clinical trials for Alzheimer's disease and Parkinson's disease.
Research on GLP-1R in neurodegeneration began with observations that GLP-1 signaling could protect neurons from various insults. Early animal studies demonstrated that GLP-1 receptor agonists could improve memory, reduce amyloid plaques, and decrease neuroinflammation.
Key milestones include the discovery of GLP-1R expression in the brain, demonstration of neuroprotective signaling pathways, and successful preclinical studies in Alzheimer's and Parkinson's disease models. Several GLP-1 receptor agonists including liraglutide, exenatide, and dulaglutide are now in clinical trials for neurodegenerative diseases.
The glucagon-like peptide-1 receptor (GLP-1R) is a G protein-coupled receptor (GPCR) expressed in the pancreas and brain that plays a crucial role in glucose metabolism and has emerged as a promising therapeutic target for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
The GLP-1R gene (located on chromosome 6p21) encodes a 463-amino acid class B GPCR protein [1]. The receptor consists of:
GLP-1 receptors are widely expressed in the central nervous system, with particularly high expression in:
This widespread distribution suggests GLP-1 signaling participates in multiple brain functions beyond glucose regulation.
Upon GLP-1 binding, GLP-1R activates Gαs protein, leading to:
GLP-1R activation engages multiple signaling pathways relevant to neuroprotection:
GLP-1R can also signal through β-arrestin pathways independent of G protein coupling, which may contribute to its neuroprotective effects [3].
Several factors make GLP-1R an attractive target for Alzheimer's disease:
Animal studies have demonstrated that GLP-1 receptor agonists:
Multiple clinical trials are evaluating GLP-1 receptor agonists in Alzheimer's disease:
| Agent | Trial Phase | Status | Outcome Measures |
|---|---|---|---|
| Liraglutide | Phase 2 | Completed | Cognition, brain volume, biomarkers |
| Exenatide | Phase 3 (PD) | Completed (Failed) | Motor outcomes - no significant benefit vs placebo |
| Semaglutide | Phase 3 (MOST-ABLE PD) | Completed | Motor outcomes, CSF biomarkers, Japanese PD patients — CSF penetration confirmed |
| Semaglutide | Phase 3 (EVOKE AD) | Failed (Nov 2025) | No CDR-SB benefit despite biomarker engagement — program discontinued |
| Tirzepatide | Phase 2 (EVOKE-Plus AD) | Recruiting | Cognitive outcomes, amyloid PET |
| Retatrutide | Phase 1 | Recruiting | Safety, pharmacokinetics |
| Dulaglutide | Phase 2 | Recruiting | Cognitive function |
The ELAD study (Evaluating Liraglutide in Alzheimer's Disease) showed some promising trends in cognition, though primary endpoints were not met [10]. The ExenD-CPD trial demonstrated good safety and some motor benefits in Parkinson's disease [11].
GLP-1 receptor agonists have demonstrated a favorable safety profile in clinical use for diabetes:
The MOST-ABLE study (Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease) is a randomized, double-blind, placebo-controlled phase 2 trial conducted in Japanese PD patients (n=99)[3:1]. This is the first oral GLP-1 formulation studied specifically in Parkinson's disease:
The EVOKE (NCT04858910) and EVOKE+ (NCT04777396) Phase 3 trials evaluated oral semaglutide (14 mg daily) in early Alzheimer's disease (n=3,808 total):
A key question for CNS applications is whether GLP-1 receptor agonists can cross the blood-brain barrier. Current evidence suggests:
GLP-1R activation reduces neuroinflammation through:
GLP-1 signaling enhances autophagy and the clearance of toxic proteins:
GLP-1R signaling preserves synaptic integrity:
GLP-1 receptor agonists may be particularly effective in combination with:
GLP-1 receptor agonists may also have therapeutic potential in atypical parkinsonian syndromes including Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP). Key considerations:
Identifying predictors of response will be important:
Athauda D., et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's Disease: a phase 3 trial. The Lancet. 2025. ↩︎
Meissner WG, et al. Trial of Lixisenatide in Early Parkinson's Disease. New England Journal of Medicine. 2024. ↩︎
Kimura Y, Koda T, Kurakami H, et al. Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study. BMJ Open. 2025. ↩︎ ↩︎